A observational study to investigate the safety and efficacy of olaparib combined with bevacizumab therapy after primary chemotherapy plus bevacizumab for Japanese patients with advanced ovarian, fallopian tube, or primary peritoneal cancer.
Not Applicable
- Conditions
- Ovarian cancer, Fallopian tube cancer, Primary peritoneal cancer
- Registration Number
- JPRN-UMIN000047107
- Lead Sponsor
- Japanese Gynecologic Oncology Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- Female
- Target Recruitment
- 300
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients with active double cancer 2. Patients judged by the investigator to be inappropriate for participation in this study
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence of adverse events
- Secondary Outcome Measures
Name Time Method -Progression-free survival (PFS) and PFS rate -Response rate in patients with residual disease (ORR) -Overall survival (OS) -Relationship to subsequent therapy, platinum-free interval -Incidence of secondary cancer